Abstract:Background: CD47 is an integral membrane protein that alters adaptive immunosurveillance when bound to the matricellular glycoprotein thrombospondin-1 (TSP1). We examined the impact of the CD47/TSP1 signaling axis on melanoma patient response to anti-PD-1 therapy due to alterations in T cell activation, proliferation, effector function, and bioenergetics. Methods: A syngeneic B16 mouse melanoma model was performed to determine if targeting CD47 as monotherapy or in combination with anti-PD-1 impacted tumor burden. Cytotoxic (CD8+) T cells from Pmel-1 transgenic mice were used for T cell activation, cytotoxic T lymphocyte, and cellular bioenergetic assays. Single-cell RNA-sequencing, ELISA, and flow cytometry was performed on peripheral blood mononuclear cells and plasma of melanoma patients receiving anti-PD-1 therapy to examine CD47/TSP1 expression. Results: Human malignant melanoma tissue had increased CD47 and TSP1 expression within the tumor microenvironment compared with benign tissue. Due to the negative implications CD47/TSP1 can have on antitumor immune responses, we targeted CD47 in a melanoma model and observed a decrease in tumor burden due to increased tumor oxygen saturation and granzyme B secreting CD8+ T cells compared with wild-type tumors. Additionally, Pmel-1 CD8+ T cells exposed to TSP1 had reduced activation, proliferation, and effector function against B16 melanoma cells. Targeting CD47 allowed CD8+ T cells to overcome this TSP1 interaction to sustain these functions. TSP1 exposed CD8+ T cells have a decreased rate of glycolysis; however, targeting CD47 restored glycolysis when CD8+ T cells were exposed to TSP1, suggesting CD47 mediated metabolic reprogramming of T cells. Additionally, non-responding patients to anti-PD-1 therapy had increased T cells expressing CD47 and circulating levels of TSP1 compared with responding patients. Since CD47/TSP1 signaling axis negatively impacts CD8+ T cells and non-responding patients to anti-PD-1 therapy have increased CD47/TSP1 expression, we targeted CD47 in combination with anti-PD-1 in a melanoma model. Targeting CD47 in combination with anti-PD-1 treatment further decreased tumor burden compared with monotherapy and control. Conclusion: CD47/TSP1 expression could serve as a marker to predict patient response to immune checkpoint blockade treatment, and targeting this pathway may preserve T cell activation, proliferation, effector function, and bioenergetics to reduce tumor burden as a monotherapy or in combination with anti-PD-1.

CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis.

CD47 Blockade Inhibits Tumor Progression Human Osteosarcoma in Xenograft Models

CD47 Masks Pro-Phagocytic Ligands in Cis on Tumor Cells to Suppress Antitumor Immunity

CD47 Blockade Triggers T Cell–mediated Destruction of Immunogenic Tumors

Role of CD47 in tumor immunity: a potential target for combination therapy

Evaluation of CD47 in the Suppressive Tumor Microenvironment and Immunotherapy in Prostate Cancer

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis

Natural Killer Cell Recruitment and Activation Are Regulated by CD47 Expression in the Tumor Microenvironment

Progress in cancer research on the regulator of phagocytosis CD47, which determines the fate of tumor cells (Review)

Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response

CD47 Signaling Regulates the Immunosuppressive Activity of VEGF in T Cells

Preclinical and Clinical Development of Therapeutic Antibodies Targeting Functions of CD47 in the Tumor Microenvironment

Is CD47 an Innate Immune Checkpoint for Tumor Evasion?

The role and progress of CD47 in immune escape of hematological malignancies

Cd47 Promotes Metastasis And Proliferation Of Colorectal Cancer Via Mapk/Erk Pathway

Abstract 4866: CD47 Promotes Metastasis and Proliferation of Colorectal Cancer Via MAPK/ERK Pathway

Vaccination with CD47 Deficient Tumor Cells Elicits an Antitumor Immune Response in Mice

Tumor CD47 Expression and a High M2/M1 Ratio of Tumor-Associated Macrophages As an Adverse Prognostic Factor in Resected Stage Ⅲa Non-Small Cell Lung Cancer.

Influence of CD47 on CD8 + T-cell and tumor prognosis based on pan-cancer analysis.

CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer

CD47 Blockade Inhibits Tumor Progression Through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer